1348-1349 / 2605
1348-1349 / 2605
Hypofractionated PBT
NCT02395523: National Cancer Center, Korea
– Hypofractionated PBT 10 x 7 Gy(RBE) 5/week
– Primary endpoint: local progression-free survival
– 40 patients, historical controls
– Estimated year of completion 2017
Source: ClinicalTrials.gov
